Immunome, Inc. (IMNM)

Market Cap	333.29M
Revenue (ttm)	10.19M
Net Income (ttm)	-21.96M
Shares Out	42.73M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,082
Open	7.57
Previous Close	7.46
Day's Range	7.40 - 7.80
52-Week Range	2.20 - 9.53
Beta	1.71
Analysts	Strong Buy
Price Target	8.00 (+2.56%)
Earnings Date	Nov 9, 2023

About IMNM

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2020
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: IMNM

Analyst Forecast

According to 2 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 2.56% from the latest price.

Price Target

$8.0

(2.56% upside)

Analyst Consensus: Strong Buy